European Pharmaceutical Review

AUGUST 2, 2023

A new COVID-19 vaccine has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA). Bimervax is now the ninth vaccine to be authorised by the UK’s independent medicines regulator to treat the virus. This is an additional ingredient designed to trigger a stronger immune response.

Vaccines 98

Vaccines Immunization 98

European Pharmaceutical Review

JULY 11, 2022

The novel coronavirus vaccine has been developed at Caltech and The University of Oxfor d. Funding of up to $30 million will support vaccine design, its development through Phase I trials and regulatory activities. . The novel vaccine, which is based on mosaic?8 How the novel coronavirus vaccine works. The novel vaccine?is

Vaccines 98

Vaccines Immunization 98

pharmaphorum

SEPTEMBER 14, 2020

AstraZeneca has resumed UK trials for its coronavirus vaccine, after the country’s medicines regulator gave the all-clear following a safety scare. Good news for everyone the Oxford vaccine trials are back up and running. We will back our scientists to deliver an effective vaccine as soon as safely possible [link].

Vaccines 104

Vaccines Immunization 104

STAT

OCTOBER 2, 2023

Overcoming a lack of broader interest in their work and scientific challenges, Katalin Karikó and Drew Weissman made key discoveries about messenger RNA that enabled scientific teams to start developing the tool into therapies, immunizations, and — as the pandemic spread in 2020 — vaccines targeting the SARS-CoV-2 coronavirus.

Immunization 145

Immunization Vaccines 145

Pharmaceutical Technology

APRIL 11, 2023

The US government is reportedly investing more than $5bn in a programme to accelerate the development of new Covid-19 vaccines and treatments. Health experts have lent their support to the new programme as the existing vaccines may not be as effective against future virus threats.

Vaccines 105

Vaccines Immunization 105

pharmaphorum

SEPTEMBER 22, 2022

Alexandre Le Vert, CEO and co-founder of Osivax, discusses the company’s breakthrough vaccine technology, oligoDOM, and how it’s driving the development of new influenza and SARS-CoV-2 vaccines that attack T-cells, providing a long-lasting effect. The technology.

Vaccines 97

Vaccines Immunization 97

European Pharmaceutical Review

NOVEMBER 1, 2023

In July 2022, the World Health Organization (WHO) released its inaugural report on the pipeline of vaccines currently in development to prevent infections caused by antimicrobial resistance (AMR) bacterial pathogens. WHO referred to 61 bacterial vaccine candidates in diverse stages of clinical development. 1 WHO’s analysis was stark.

Vaccines 115

Vaccines Immunization 115

pharmaphorum

OCTOBER 5, 2022

million grant by the US government to develop an intranasal vaccine for gonorrhoea, a sexually-transmitted infection that is on the rise around the world. million in National Institutes of Health (NIH) funding to further develop a prophylactic vaccine based on its proprietary outer membrane vesicles (OMV) platform technology.

Vaccines 98

Vaccines Immunization 98

Pharmaceutical Technology

NOVEMBER 25, 2022

XtalPi has entered a strategic partnership with CK Life Sciences for artificial intelligence (AI)-driven tumour vaccine research and development (R&D). Under the collaboration, the companies will utilise their capabilities to co-develop a new AI tumour vaccine R&D platform.

Vaccines 98

Vaccines Immunization Process Improvement Compounding 98

pharmaphorum

JANUARY 13, 2021

IO Biotech, an oncology specialist formed and backed by Denmark’s Novo Holdings, has raised €127 million ($155 million) to further develop its cancer vaccine technology that has boosted efficacy of PD-1 immunotherapy in early trials. The post IO Biotech raises $155m to develop breakthrough cancer vaccine appeared first on.

Vaccines 95

Vaccines Immunization Compounding 95

pharmaphorum

JULY 27, 2022

Pfizer and BioNTech have started a mid-stage trial of a new version of the COVID-19 vaccine based on a version of the spike protein that they hope will offer greater and broader protection against SARS-CoV-2 variants. Feature image copyright BioNTech SE 2020, all rights reserved. 1 subvariant of Omicron.

Vaccines 122

Vaccines Immunization FDA 122

European Pharmaceutical Review

DECEMBER 19, 2023

Many of today’s vaccines are produced in ready-to-inject liquid formulations that must be kept cold to maintain stability. However, this greatly complicates both the worldwide distribution and stockpiling of vaccines and other drugs. A requisite cold chain has been designed and implemented to be uninterrupted from factory to patient.

Vaccines 111

Vaccines Communication Immunization Documentation 111

European Pharmaceutical Review

MARCH 9, 2023

Findings from research on the nasal monoclonal antibody “Based on our studies, we expect that Foralumab may work on all variants as it acts on immune effects,” Dr Weiner continued. Foralumab’s immune modulating response In 2020, Moreira researched how Foralumab modulates the immune response to reduce inflammation.

Immunization 145

Immunization Medical Schools Vaccines Hospitals 145

pharmaphorum

DECEMBER 22, 2020

BioNTech CEO Ugur Sahin has said that it is “highly likely” the company’s COVID-19 vaccine will work against the more infectious strain circulating in the south east of England, although further studies will be needed. Sahin said: “We don’t know at the moment if our vaccine is also able to provide protection against this new variant.

Vaccines 81

Vaccines Immunization 81

Pharmaceutical Technology

AUGUST 15, 2022

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional authorisation for Moderna ’s Covid-19 booster vaccine, mRNA-1273.214 (Spikevax Bivalent Original/Omicron), for use in adults aged 18 years and above. It comprises mRNA-1273 (Spikevax) and a vaccine candidate that acts on the SARS-CoV-2 virus’ BA.1

Vaccines 85

Vaccines Immunization 85

pharmaphorum

MAY 10, 2021

BioNTech has said it plans to set up a regional base and new manufacturing site in Singapore so that the biotech can keep pace with demand for its mRNA-based coronavirus vaccine and pipeline products in other disease areas. Feature image copyright BioNTech SE 2020, all rights reserved.

Vaccines 129

Vaccines Immunization 129

Hospital Pharmacy Europe

DECEMBER 14, 2022

mRNA-4157/V940 which represents a personalised cancer vaccine has been found effective when combined with pembrolizumab in advanced melanoma. Melanoma of the skin is the 17th most common cancer worldwide and in 2020, there were 324,635 new cases and 57,043 deaths. For example, regional melanoma (stage 3) has a 63.6%

Vaccines 98

Vaccines Immunization Hospitals 98

European Pharmaceutical Review

AUGUST 26, 2022

Moderna has filed patent infringement lawsuits alleging that Pfizer and BioNTech’s COVID-19 vaccine Comirnaty ® infringes patents Moderna filed between 2010 and 2016 covering its foundational messenger RNA (mRNA) technology. Pfizer and BioNTech copied this technology, without Moderna’s permission, to make Comirnaty,” said Moderna.

Vaccines 98

Vaccines Immunization 98

BuzzRx

SEPTEMBER 26, 2022

During the COVID-19 pandemic , the first year’s flu season (2020) was a minor one due to the measures undertaken to prevent coronavirus. When someone recovers from infectious diseases like the flu or COVID-19, they retain some natural immunity that protects them from future infections. I got the flu vaccine last year.

Vaccines 98

Vaccines Immunization Hospitals 98

pharmaphorum

AUGUST 10, 2021

BioNTech has suggested that giving booster doses of its current Comirnaty (BNT162b2) COVID-19 vaccine may be a preferable strategy to modifying the Pfizer-partnered shot. “It is quite possible that in the next six months to 12 months further variants emerge and that would require adaptation of the vaccine,” he added.

Vaccines 116

Vaccines Immunization 116

pharmaphorum

DECEMBER 6, 2021

A trial of booster vaccinations to protect against COVID-19 has shown that the jab significantly strengthens the body’s T-cell immunity against the disease. Several COVID-19 vaccines were used in the trial – all were administered via intramuscular injection into the upper arm.

Immunization 52

Immunization Vaccines Hospitals 52

pharmaphorum

JANUARY 10, 2023

Since then, the two partners have developed multiple AI-based applications including a platform for selecting neoantigens for use in individualised cancer vaccines and an early warning system for high risk SARS-CoV-2 variants based on how well they can evade the immune system and their transmissibility.

Immunization 116

Immunization Vaccines 116

pharmaphorum

JANUARY 5, 2022

GlaxoSmithKline places shingles vaccine Shingrix is among its top prospects, with peak sales potential of almost $6 billion. Shingrix was dubbed the “crown jewel” of GSK’s vaccine franchise at the company’s latest R&D update. Now, Pfizer and BioNTech are joining forces to try to grab a slice of the market.

Vaccines 105

Vaccines Immunization FDA 105

pharmaphorum

AUGUST 16, 2021

Pfizer and BioNTech have formally asked for FDA approval of a third dose of their COVID-19 vaccine BNT162b2 in people aged over 16, as the US prepares to get its booster campaign underway. Mixing of the two mRNA vaccines is permitted for the third shot if the original vaccine received by a person is not available, according to the agency.

FDA 105

FDA Vaccines Immunization 105

Pharmaceutical Technology

JUNE 29, 2022

The Japanese Ministry of Health, Labour and Welfare (MHLW) has accepted GlaxoSmithKline’s (GSK) regulatory application for recombinant, adjuvanted Zoster vaccine, Shingrix, for preventing shingles (herpes zoster) in at-risk adults of the age 18 years and above.

Vaccines 64

Vaccines Immunization 64

pharmaphorum

DECEMBER 21, 2020

Moderna and BioNTech, two rising stars in biotech, were in the limelight this year with their pioneering mRNA vaccines against COVID-19. But the tragic events of 2020 have meant these companies have become household names as their trailblazing mRNA vaccines became the first to be approved by regulators against the COVID-19 scourge.

Vaccines 111

Vaccines Immunization 111

Pharmaceutical Technology

JUNE 30, 2022

HDT Bio has received Emergency Use Approval from Indian regulators for its Covid-19 vaccine, Gemcovac. The vaccine leverages self-amplifying RNA (saRNA), which can replicate itself after administration and could be effective at very low doses. HDT Bio CEO Steve Reed said: “Our saRNA vaccine is a game-changer.

Vaccines 64

Vaccines Immunization 64

pharmaphorum

AUGUST 6, 2021

billion from sales of just under 200 million doses of its COVID-19 vaccine, taking its tally since approval to around $6 billion from 302 million shots. The tally makes the SpikeVax (mRNA-1273) vaccine the second biggest seller behind Pfizer/BioNTech’s Comirnaty, which pulled in $7.8 Moderna made a massive $4.2

Vaccines 105

Vaccines Immunization 105

Hospital Pharmacy Europe

JULY 10, 2024

The UK is switching to a different pertussis vaccine for pregnant women following advice from the Joint Committee on Vaccination and Immunisation. Analysis showed antibody levels to polio type 2 were most affected by the maternal vaccination.

Vaccines 59

Vaccines Immunization Hospitals 59

pharmaphorum

MAY 9, 2022

vaccine to treatment with Roche’s cancer immunotherapy Tecentriq resulted in disease control in two-thirds of patients with advanced cervical cancer. is an ‘off-the-shelf’ vaccine based on a standardised formulation, but the underlying technology is the same as for VB10.NEO Adding Nykode Therapeutics’ VB10.16

Vaccines 64

Vaccines Immunization 64

pharmaphorum

JULY 9, 2021

With the COVID-19 delta variant has become the dominant strain circulating in the US, Pfizer and BioNTech have said they will ask the FDA and other regulators to approve a third dose of their Comirnaty vaccine to guard against a winter surge in cases. . Feature image copyright BioNTech SE 2020, all rights reserved.

Vaccines 98

Vaccines Immunization FDA 98

pharmaphorum

JANUARY 10, 2022

The arrival of COVID-19 brought precious few positives, but one that emerged for the pharmaceutical industry was the emergence and validation of mRNA vaccine technology to prevent disease. Pfizer already has a head start on competitors in the field, having achieved the first US FDA approval for an mRNA vaccine, alongside BioNTech.

Vaccines 111

Vaccines Immunization FDA 111

The Checkup by Singlecare

APRIL 11, 2024

When the immune system gets weakened by age or emotional or physical stressors, the virus can reactivate and cause shingles. Shingrix is an injectable vaccine that helps prevent shingles. Recommended by the Centers for Disease Control and Prevention , it’s the only available vaccine of its kind still in use. ml vaccine.

Vaccines 85

Vaccines Insurance Assisted Living Hospitals 85

pharmaphorum

MAY 20, 2021

All seven COVID-19 vaccines ordered by the UK government will be tested in a new trial that will see whether they can be used as a third booster dose to protect against new variants. . A control group will get a meningococcal vaccine. It brings it back to the race between vaccine and virus, expect the virus just got faster”.

Vaccines 98

Vaccines Immunization Hospitals 98

pharmaphorum

JANUARY 25, 2022

Pfizer and partner BioNTech have started their clinical trial of a new version of their COVID-19 vaccine that has been specifically designed to protect against the Omicron variant. Feature image copyright BioNTech SE 2020, all rights reserved. The post Pfizer starts dosing patients with its Omicron COVID shot appeared first on.

Vaccines 98

Vaccines Immunization 98

Hospital Pharmacy Europe

NOVEMBER 24, 2022

A fentanyl vaccine induced significant antibody levels and reduced brain levels of the drug and could be of value in opiate use disorder. The principle is simple: a conjugate vaccine is designed to elicit an immune response to the abused opioid (e.g., Fentanyl vaccine effectiveness. Citation Haile CN et al.

Vaccines 59

Vaccines Immunization Hospitals 59

European Pharmaceutical Review

NOVEMBER 10, 2023

The US Food and Drug Administration (FDA) has approved Valneva SE’s IXCHIQ ® , the first chikungunya vaccine to be authorised in the world. The single-dose, live-attenuated vaccine is indicated for preventing chikungunya virus disease in individuals over 18 years old who are at increased risk of contracting the virus.

Vaccines 52

Vaccines Adverse Reactions FDA Immunization 52